Skip to main
VANI
VANI logo

VANI Stock Forecast & Price Target

VANI Analyst Ratings

Based on 1 analyst ratings
Strong Buy
Strong Buy 100%
Buy 0%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Vivani Medical Inc. is positioned favorably in the biopharmaceutical market due to its proprietary NanoPortal technology, which facilitates the sustained delivery of medications for chronic diseases. The company’s candidate NPM-139 shows promising results, particularly in improving the safety and tolerability profile of existing therapies like semaglutide, with reported patient outcomes indicating an approximate 20% weight loss maintained for over six months. Given the encouraging data supporting NPM-139's advancement into clinical development, the company's prospects appear positive as it addresses significant needs in patient compliance and therapy adherence.

Bears say

Vivani Medical Inc. faces significant risks that contribute to a negative outlook on its stock. The company’s lead product, NPM-139, is highly dependent on successful clinical trials and obtaining regulatory approval, both of which are uncertain and could hinder its path to market. Additionally, challenges related to market size, penetration rates, competition, and potential dilution further exacerbate the company's financial vulnerabilities and decrease investor confidence.

VANI has been analyzed by 1 analysts, with a consensus rating of Strong Buy. 100% of analysts recommend a Strong Buy, 0% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Vivani Medical Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Vivani Medical Inc (VANI) Forecast

Analysts have given VANI a Strong Buy based on their latest research and market trends.

According to 1 analysts, VANI has a Strong Buy consensus rating as of Oct 15, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $4, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $4, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Vivani Medical Inc (VANI)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.